PET Dynamic Imaging and Quantification
Kinetic metrics changes of FDG in key organs after chemo-immunotherapy in patients with locally advanced non-small cell lung cancer identified by total-body PET/CT dynamic imaging
Mo Yiwen, Liu Hui, Wei Yuan, Li Xinling, Li Ruping, Zhang Xu, Fan Wei
Published 2022-12-25
Cite as Chin J Nucl Med Mol Imaging, 2022, 42(12): 719-723. DOI: 10.3760/cma.j.cn321828-20221017-00310
Abstract
ObjectiveTo evaluate the kinetic metrics changes of FDG in key organs after chemo-immunotherapy in patients with locally advanced non-small cell lung cancer (NSCLC) identified by total-body PET/CT dynamic imaging, and explore its potential biological significance.
MethodsFrom August 2020 to March 2021, 16 patients (13 males, 3 females; age: 43-67 years) with locally advanced NSCLC who underwent total-body 18F-FDG PET/CT dynamic imaging in Sun Yat-sen University Cancer Center were retrospectively analyzed. ROIs of key organs were drawn at baseline and after chemo-immunotherapy to obtain the time-activity curves (TACs). The kinetic metrics, including K1, k2, k3 and metabolic rate of FDG (MRFDG), were fitted by the two-tissue compartment model. Paired t test or Wilcoxon signed rank test was used to compare the differences of FDG kinetic parameters in each organ before and after treatment.
ResultsCompared with baseline, SUVmax of colon (3.23±1.29 vs 4.81±2.73), MRFDG ((2.77±1.96) vs 3.56(1.07, 9.89) μmol·100 g-1·min-1) of lungs, SUVmax (2.16±0.27 vs 2.33±0.41), k3 ((0.008±0.002) vs (0.012±0.004) min-1) and MRFDG ((2.65±0.81) vs (3.76±1.59) μmol·100 g-1·min-1) of spleen, and SUVmax (2.59±0.45 vs 4.49±2.73), k2 ((0.76±0.37) vs (1.27±0.66) min-1), k3 ((0.032±0.007) vs (0.066±0.029) min-1) and MRFDG ((5.14±1.44) vs (8.39±2.67) μmol·100 g-1·min-1) of bone marrow were increased after chemo-immunotherapy with significant differences (t values: from -5.40 to 3.47, z=-2.02, all P<0.05). There were no significant differences of SUVmax, k values and MRFDG in other organs (t values: from -2.00 to 2.35, z values: from -1.45 to -0.05, all P>0.05).
ConclusionsAfter chemo-immunotherapy, the activation of immune system may be manifested as the increase of FDG kinetic rate constants in spleen and bone marrow. The lung and colon may be target organs for immune-related adverse effects.
Key words:
Carcinoma, non-small-cell lung; Drug therapy, combination; Immunotherapy; Pharmacokinetics; Positron-emission tomography; Tomography, X-ray computed; Fluorodeoxyglucose F18
Contributor Information
Mo Yiwen
Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Liu Hui
Department of Radiotherapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Wei Yuan
Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Li Xinling
Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Li Ruping
Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Zhang Xu
Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Fan Wei
Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China